76,116 Shares in Grifols, S.A. (NASDAQ:GRFS) Bought by Compass Wealth Management LLC

Compass Wealth Management LLC acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 76,116 shares of the biotechnology company's stock, valued at approximately $541,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its position in shares of Grifols by 14.9% in the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Grifols by 66.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 60,063 shares of the biotechnology company's stock worth $427,000 after buying an additional 23,980 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Grifols by 20.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 266,005 shares of the biotechnology company's stock valued at $1,891,000 after acquiring an additional 44,818 shares during the last quarter. NBC Securities Inc. raised its holdings in Grifols by 112,543.1% during the first quarter. NBC Securities Inc. now owns 57,448 shares of the biotechnology company's stock worth $408,000 after acquiring an additional 57,397 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Grifols by 426.1% in the first quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock valued at $1,850,000 after purchasing an additional 21,128 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GRFS shares. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th.

Grifols Price Performance

Shares of GRFS stock traded down $0.17 during trading on Monday, hitting $8.92. The company had a trading volume of 122,079 shares, compared to its average volume of 1,115,561. The stock's 50-day moving average price is $8.24 and its 200 day moving average price is $7.70. Grifols, S.A. has a one year low of $6.19 and a one year high of $9.96. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The firm has a market capitalization of $6.13 billion, a P/E ratio of 7.62, a price-to-earnings-growth ratio of 0.33 and a beta of 0.55.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.